Beyond the Scale: My GLP-1 Journey

The creator of the channel Beyond the Scale: My GLP-1 Journey says the claim that Medicare Part D ends on January 1, 2027 is not true.

1. 0:00 Introduction and is Medicare Part D ending?
2. 2:27 The temporary assistance that IS ending at the end of 2026
3. 3:48 Why premiums could go up in 2027 for some Part D enrollees
4. 4:46 Two numbers in 2027 that every Medicare beneficiary taking p
5. 6:37 Why your medications matter when comparing Medicare plans in
6. 7:32 What the end of the Premium Stabilization Demonstration mean
7. 8:31 Medicare is negotiating the price of Semaglutide
8. 9:59 What about the Medicare GLP-1 Bridge?

• Who is speaking: Patient

According to the video, CVS has announced changes to its weight management program that bring several GLP-1 services into one system.

1. 0:00 Introduction and what CVS just announced
2. 1:26 The $29 MinuteClinic vist
3. 2:33 The new CVS and Eli Lilly partnership
4. 3:13 Same-day pickup, which GLP-1 medications are available, and
5. 4:51 The good news for Medicare beneficiaries
6. 5:30 What the CVS GLP-1 change really means

• Prices mentioned: $25 a month and $50 a month
• Who is speaking: Patient

According to the video, Eli Lilly has launched the Zepbound QuickPen, a multi-dose, single patient use prefilled pen that holds four weekly doses of tirzepatide. The creator says it replaces the weekly auto-injector or the vial-and-syringe routine, so one pen covers a month.

1. 0:00 Introduction and What is the Zepbound KwikPen?
2. 1:18 Zepbound KwikPen available doses and who it's approved for
3. 2:05 Zepbound KwikPen prices and how to get it
4. 2:39 How is the Zepbound KwikPen different from current options?
5. 3:12 Why this matters and what to keep in mind when considering t

• Doses mentioned: 2.5 mg
• Prices mentioned: $299 a month
• Who is speaking: Patient

The creator explains a catch in the Medicare GLP-1 Bridge Program, which she says launched in July 2026 as a temporary demonstration.

1. 0:00 Intro and the Medicare Bridge catch that people may not be a
2. 0:55 What is the Medicare Bridge program?
3. 1:44 Here's where things get complicated
4. 3:28 Meet Jeff La Marca
5. 5:11 So what happens next?
6. 8:14 Why did Medicare create this system in the first place?
7. 9:43 Another question we need to ask
8. 10:47 So where does that leave Medicare patients?

• Prices mentioned: $50 a month
• Who is speaking: Patient

Stephanie, who runs a channel about her own GLP-1 treatment, explains how she handled moving from the 2.5mg dose of Zepbound to the 5mg dose, including how her insurance treated the change.

• Doses mentioned: 2.5 mg and 5 mg
• Who is speaking: Patient

According to the video, Amazon has launched a GLP-1 management program through Amazon One Medical.

1. 0:00 What Amazon just announced about GLP-1 medications and what
2. 0:59 Amazon One Medical GLP-1 Management Program overview and wha
3. 2:14 The real advantage to Amazon's GLP-1 program and what you ne
4. 3:22 What Amazon's GLP-1 program will impact and where it may fal

• Prices mentioned: $25 a month, $149 a month and $299 a month
• Who is speaking: Patient

Stephanie, who runs the channel Beyond the Scale and says she documents her own Zepbound journey, compares the three medications covered by the Medicare GLP-1 bridge program: Wegovy, Zepbound and Foundayo.

1. 0:00 Introduction and who qualifies for the Medicare Bridge Progr
2. 2:11 Let's Meet the Three Covered GLP-1 Medications in the Medica
3. 5:53 Which GLP-1 Medication Might Fit Different People?
4. 6:39 Side Effects: What Do They Have in Common?
5. 8:43 What If You Are On Medicare and Have Type 2 Diabetes?
6. 9:15 So...Which GLP-1 Medication Is Right for You?

• Prices mentioned: $50 a month
• Who is speaking: Patient

According to the video, Eli Lilly's oral GLP-1 medication orforglipron is in phase three clinical trials for type 2 diabetes, for weight management in adults with obesity or overweight and at least one weight related health condition, and for obstructive sleep apnea in people with obesity.

1. 0:00 Introduction to orforglipron
2. 0:54 Clinical trial results
3. 2:03 Weight loss findings
4. 2:35 Comparison with Zepbound
5. 3:23 Pricing and market outlook

• Who is speaking: Patient

According to the video, the FDA has approved a new weight loss pill called Foundeo, also known as orforglipron, made by Eli Lilly. The creator describes it as a once-daily GLP-1 pill and the first non-peptide GLP-1 pill.

1. 0:00 Introduction and What Is Foundayo?
2. 1:25 How Much Weight Can You Lose With Foundayo?
3. 2:00 Why Is Foundayo Such a Big Deal?
4. 2:36 What Are the Side Effects and Risks Associated with Foundayo
5. 3:17 The Bigger Trend with GLP-1 Medication
6. 3:57 The Costs and Access for Foundayo and Wrap-up

• Prices mentioned: $25 a month and $50 a month
• Who is speaking: Patient